COVID-19 antiviral treatment arrives in Nova Scotia - CBC.ca | Canada News Media
Connect with us

Business

COVID-19 antiviral treatment arrives in Nova Scotia – CBC.ca

Published

 on


Nova Scotia says 900 treatment packages of the COVID-19 antiviral drug have landed in the province, but plans for prescribing Paxlovid are still being finalized.

The Health and Wellness Department said it is working to make the supply available “as soon as possible,” and details about the distribution of Pfizer’s Paxlovid are still being worked out with stakeholders including Nova Scotia Health.

Earlier this week, Health Canada approved the oral antiviral treatment designed to help the body fight off the virus, reduce symptoms from an infection and shorten the period of illness.

Dr. Lisa Barrett, who treats COVID-19 patients and will prescribe the therapeutic once it starts rolling out, said a plan for distribution could take another few weeks.

But she said the first 900 treatment packages will help 900 people. The drug is taken twice a day for five days. 

Dr. Lisa Barrett is an infectious disease specialist based out of Dalhousie University in Halifax. (CBC)

It will be made available to the most vulnerable, including those who are not fully vaccinated for one reason or another and people over the age of 50 who have a risk factor such as being a transplant or cancer patient. 

“We’re hoping that it’s going to make a difference for the most vulnerable people,” said Barrett in an interview on Thursday.

“This is for people at the highest risk of disease and we don’t want them to have to shield anymore at home.”

Barrett noted the medication is designed to reduce hospitalization and death. The hope is that it will help alleviate pressures on the health-care system, she said.

Recognizing the limitations

She also said the fact that the drug is only trickling into the province at this point does not concern her because it was studied on unvaccinated people who were at high risk with the Delta variant. 

“It’s not clear yet if there is as much of a benefit to preventing hospitalization and death in people who are partly vaccinated, but not fully, against Omicron,” said Barrett.

“I want people to be aware we’re not completely devastated that we don’t have hundreds of thousands of doses of this because we think it’s helpful but not for the whole population.

“It’s good to recognize the limitations of the data and where we sit right now.”

Barrett said those in the vulnerable population group should be tested as soon as possible if they have symptoms and report any positive results to Public Health and their doctor.

Doctors will be able to refer their patients to receive the drug. Those referrals will be reviewed and the patient will be contacted about how to receive the treatment.

She said outbreaks in hospitals and long-term care homes will also be monitored as a way of identifying people at risk who may need the treatment. 

Recent approval of drug ‘great news’

On Monday, Canada’s Chief Public Health Officer Dr. Theresa Tam said Health Canada’s approval was “great news” because Paxlovid could drive down severe outcomes in the current wave and beyond.

Paxlovid combines a new drug developed by Pfizer called nirmatrelvir with an existing antiretroviral drug named ritonavir, a low-dose HIV drug that helps nirmatrelvir remain active in the body longer.

After months of clinical trials, Pfizer reported in November that Paxlovid reduced the risk of hospitalization or death by 89 per cent compared to a placebo in non-hospitalized high-risk adults with COVID-19.

MORE TOP STORIES

Adblock test (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version